冬凌草单药及与化疗合用治疗食管癌205例

目的:观察冬凌草单药及与化疗合用治疗食管癌的临床疗效.方法:448例患者,均经病理细胞学和X线检查确诊为食管癌.其中早期癌76例,均采用冬凌草单药治疗.晚期癌372例,167例采用冬凌草单药治疗,205例采用冬凌草与化疗合用.结果:用冬凌草单药治疗早期食管癌患者3,5,10,13 a的生存率明显高于未治疗组(98.68% vs 51.52%,84.02% vs 28.62%,63.49% vs 11.45%,50.13% vs 8.59%;P<0.001).对于晚期食管癌,冬凌草联合化疗应用,其总有效率明显高于以PYM(BLM)为基础的单一化疗(66.82% vs 42.85%,P<0.01).冬凌草与化疗合用组与单一化疗对照组相比副作用基本相同,无明显差异(P>0.05).结论:对于早期食管癌患者,冬凌草能控制疾病发展延长生存时间;对于晚期食管癌患者,冬凌草能增强化疗的作用.

Clinical efficacy of treatment by Rabdosia rubescens alone or in combination chemotherapy for esophageal cancer

AIM:To observe the clinical efficacy of Rabdosia rubescens alone or in combination chemotherapy for the treatment of esophageal cancer patients. METHODS:We enrolled 448 patients diagnosed with esophageal cancer by pathology and X-ray; 76 in the early stage were treated with Rabdosia rubescens alone;372 were in the middle to late stage and among these,167 were treated with Rabdosia rubescens alone,while 205 were treated with Rabdosia rubescens plus chemotherapy. RESULTS:For early-stage esophageal cancer patients treated with Rabdosia,survival rates at 3,5,10 and 13 years were significantly higher than those for patients without treatment(98.68% vs 51.52%,84.02% vs 28.62%,63.49% vs 11.45%, 50.13% vs 8.59%;P<0.001).For late-stage esoph- ageal cancer,the response rate to Rabdosia rubes- cens plus chemotherapy was significantly higher than that in PYM-BLM based chemotherapy alone(66.82% vs 42.85%,P<0.01).There was no significant difference regarding side effects be- tween Rabdosia rubescens plus chemotherapy and chemotherapy alone(P>0.05). CONCLUSION:For early-stage esophageal can- cer,Rabdosia rubescens appears to control disease and prolong survival time.Rabdosia rubescens also appears to enhance the effect of chemother- apy against advanced esophageal cancer.